louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00800397: Evaluation of the Noga System: Detecting of Respiratory Related Sleep Disorders in Cardiac Patients
Official title: Evaluation of the Noga System: Detecting of Respiratory Related Sleep Disorders in Cardiac Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sleep Apnea
Lead sponsor: WideMed LTD.
Sponsor class: INDUSTRY
First posted: 2008-12-02
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: cardiac and suspected sleep disordered breathing patients

Brief summary: Medical literature has shown that 1 out of 2 patients that are admitted to the hospital as a cardiac patient, will be found suffering from sleep breathing disorders. The medical literature also shows that there is an advantage of treating the sleep breathing disorders in addition to treating the cardiac disease or evaluating the heart failure condition to provide better clinical outcomes.this study is evaluating the ability to detect sleep and cardiac related breathing disordered.


Eligibility criteria: Inclusion Criteria:

1. Patient is hospitalized in the cardiology department or in the sleep lab.
2. Patients who is willing and able to tolerate a full night Polysomnography
3. Patient is not receiving oxygen treatment
4. Patients is 18 years of age or above
5. Patient is able and willing to sign the institution human subjects committee approved Informed Consent Form.

Exclusion Criteria:

1. Patients can not tolerate a full night Polysomnography.
2. Patient is receiving oxygen.
3. Participation in a clinical trial within the last 60 days and during the study.
4. Life expectancy \< 1 month.

Primary outcomes:
measure: Detection of Cheyne Stokes respiration
timeFrame: over night
Secondary outcomes:
measure: Sleep and sleep apnea parameters
timeFrame: over night
measure: AH>=15
timeFrame: over night
measure: plethysmography derived respiration signal
timeFrame: over night
measure: Total duration of Cheyne Stokes
timeFrame: over night
Other outcomes:
Locations:
city: Morristown
country: United States
facility: Morristown memorial hospital
state: New Jersey
Study officials:
References:
Clinical trial NCT01612897: Study of the Effectiveness of a Computer Decision Support System to Improve Physicians' Screening for Autism
Official title: Computer Assisted Autism Care (CAAC)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Children Undergoing Routine Care
Children With Autism
Keywords: autism
well child care
screening
computer
reminders
Lead sponsor: Indiana University
Sponsor class: OTHER
First posted: 2012-06-06
Enrollment: 368
Sex: ALL
Minimum age (years): 17
Maximum age (years): 4
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The investigators hypothesize that children seen in a clinic that uses a compute based system known as CHICA, which reminds pediatricians to screen at defined time point for autism, will be screened more consistently for autism and receive more timely diagnostic a treatment services.

Detailed description: To be eligible for this trial, participants must receive their care at one of four primary care clinics in Indianapolis where the CHICA system is used.

Eligibility criteria: Inclusion Criteria:

* Previously healthy children receiving routine care in one of four clinics in Indianapolis who participate in this study.

Exclusion Criteria:

* Previously known autism spectrum disorders or other causes of developmental delay

Primary outcomes:
measure: Structure autism screening instrument administered
timeFrame: Up to 4 years
Secondary outcomes:
measure: Are appropriate diagnostic studies conducted among children who screen positive for autism.
timeFrame: Up to 4 years
Other outcomes:
Locations:
city: Indianapolis
country: United States
facility: Wishard (Eskenazi) Healthcare clinics
state: Indiana
Study officials:
References:
citation: Downs SM, Bauer NS, Saha C, Ofner S, Carroll AE. Effect of a Computer-Based Decision Support Intervention on Autism Spectrum Disorder Screening in Pediatric Primary Care Clinics: A Cluster Randomized Clinical Trial. JAMA Netw Open. 2019 Dec 2;2(12):e1917676. doi: 10.1001/jamanetworkopen.2019.17676.
Clinical trial NCT04576897: Velacur by Sonic Incytes for Portal Hypertension
Official title: Non-invasive Evaluation of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease by Liver Stiffness Measurement Using Liver Incytes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Portal Hypertension
Chronic Advanced Liver Disease
Lead sponsor: Indiana University
Sponsor class: OTHER
Collaborators: name: Sonic Incytes
First posted: 2020-10-06
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: All participants will undergo quantitative ultrasound with Velacur by Sonic Incytes by a certified technician.
Primary purpose: DIAGNOSTIC

Brief summary: This is a cross sectional study that evaluates the relationship between LSM (liver stiffness measurement) by Liver Incytes in patients with cACLD (compensated advanced chronic liver disease) and manifestations of portal hypertension.

Detailed description: The purpose of this study is to assess the severity of portal hypertension in people with compensated advanced chronic liver disease (cACLD) who have not undergone liver transplant by measuring liver stiffness with the Liver Incytes device (Velacur) and comparing the performance of LSM (liver stiffness measurement) via Velcaur and transient elastography via FibroScan to esophageal varices.

Eligibility criteria: Inclusion Criteria:

1. Adults aged 18 years or older
2. Ability to provide informed consent
3. Planned standard of care upper endoscopy to screen for varices
4. Planned standard of care transjugular liver biopsy with portal pressure measurement

Exclusion Criteria:

1. Inability or refusal to provide informed consent
2. Fasting for less than three hours prior to the scan
3. Subject is a pregnant or lactating female
4. Subject with current, significant alcohol consumption
5. Patients with a pacemaker or defibrillator
6. Acute hepatitis defined as AST/ALT \> 500 U/L
7. Ascites
8. post liver transplantation

Primary outcomes:
measure: Liver Stiffness Measurements for Participants With Compensated Advanced Chronic Liver Disease With and Without Esophageal Varices Upon Esophagogastroduodenoscopy (EGD)
timeFrame: one day
measure: Platelet Count for Participants With Compensated Advanced Chronic Liver Disease
timeFrame: one day
Secondary outcomes:
Other outcomes:
measure: Correlation of Velacur Measurements to Non-Invasive Blood Markers for Predicting Advanced Fibrosis
timeFrame: one day
Locations:
city: Indianapolis
country: United States
facility: Indiana University Division of Gastroenterolgy and Hepatology
state: Indiana
Study officials:
affiliation: Indiana University
name: Samer Gawrieh, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06983197: Iatrogenic Deficiencies in ICU Patients With Prolonged Continuous Renal Replacement Therapy
Official title: Iatrogena bristtillstånd Hos intensivvårdade Patienter Under långvarig Behandling Med Kontinuerlig Dialys
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Acute Kidney Injury
Lead sponsor: Karolinska University Hospital
Sponsor class: OTHER
First posted: 2025-05-21
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient of all ages treated with CRRT

Brief summary: ICU patients are recruited after at least 5 days treatment with continuous renal replacement therapy. Blood samples are drawn at time of recruitment and then every 3-5 days until ceseation of renal replacement therapy.

Samples will be analyzed for concentrations of trace elements, vitamins and amino acids.

10 adult ICU patients treated for two weeks without renal replacement therapy will be sampled at one time point to serve as controls.


Eligibility criteria: Inclusion Criteria CRRT group:

* CRRT more than 5 days

Exclusion Criteria:

* N/A

Inclusion criteria non-CRRT group

- ICU care 10-15 days without any dialysis treatment

Primary outcomes:
measure: Concentration of trace element
timeFrame: From enrollment to the end of treatment at 4 weeks
Secondary outcomes:
measure: Amino acids
timeFrame: From enrollment to the end of treatment at 4 weeks
measure: Vitamins
timeFrame: At all measuring points
Other outcomes:
Locations:
Study officials:
affiliation: Karolinska University Hospital
name: Jonathan Grip, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04891497: Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke
Official title: Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Acute Ischemic Stroke
Keywords: Acute Ischemic Stroke
Immune Modulator
Dimethyl Fumarate
Intraarterial Treatment
Lead sponsor: Xuanwu Hospital, Beijing
Sponsor class: OTHER
First posted: 2021-05-18
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in combination with intraarterial treatment in patients with Acute Ischemic Stroke.


Eligibility criteria: Inclusion Criteria:

1.18-80 years old 2. NIHSS score\>6 3. For the first stroke, MRI showed anterior circulation infarction 4. Patients who meet the mechanical thrombectomy treatment by MRI assessment within 24 hours

Exclusion Criteria:

1. Patients receiving Alteplase thrombolysis
2. Other diseases of the central nervous system
3. There has been a neurological disability in the past (mRS score\>2)
4. Difficulty swallowing
5. Arrhythmia, atrioventricular block
6. Use of anti-tumor drugs, other immunosuppressive and immunomodulatory drugs
7. Macular edema
8. Magnetic resonance angiography shows vertebra-basilar artery obstruction
9. Hemorrhagic stroke
10. Patients who are known to have hypersensitivity to dimethyl fumarate or any excipients of this product
11. Pregnant and lactating women

Primary outcomes:
measure: lesion volume
timeFrame: day 1
measure: hemorrhage volume
timeFrame: day 1
measure: National Institutes of Health Stroke Scale (NIHSS)
timeFrame: day 1
Secondary outcomes:
measure: lesion volume
timeFrame: day3
measure: lesion volume
timeFrame: day7
measure: lesion volume
timeFrame: day90
measure: hemorrhage volume
timeFrame: day3
measure: hemorrhage volume
timeFrame: day7
measure: hemorrhage volume
timeFrame: day14
measure: hemorrhage volume
timeFrame: day90
measure: National Institutes of Health Stroke Scale (NIHSS)
timeFrame: day3
measure: National Institutes of Health Stroke Scale (NIHSS)
timeFrame: day7
measure: National Institutes of Health Stroke Scale (NIHSS)
timeFrame: day14
measure: National Institutes of Health Stroke Scale (NIHSS)
timeFrame: day90
measure: The Modified Rankin Scale (mRS)
timeFrame: day1
measure: The Modified Rankin Scale (mRS)
timeFrame: day3
measure: The Modified Rankin Scale (mRS)
timeFrame: day7
measure: The Modified Rankin Scale (mRS)
timeFrame: day14
measure: The Modified Rankin Scale (mRS)
timeFrame: day90
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02108197: Sleep Apnea and Gestational Diabetes
Official title: Obstructive Sleep Apnea and Gestational Diabetes : Incidence and Effects of Continuous Positive Airway Pressure Treatment on Glucose Metabolism
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gestational Diabetes
Sleep Apnea
Lead sponsor: Ramathibodi Hospital
Sponsor class: OTHER
First posted: 2014-04-09
Enrollment: 82
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators hypothesize that pregnant women with gestational diabetes will have a high incidence of sleep apnea, and that the treatment of sleep apnea will lead to improved glucose control in these women.


Eligibility criteria: Inclusion Criteria:

* gestational diabetes

Exclusion Criteria:

* pre-gestational diabetes

Primary outcomes:
measure: glucose tolerance
timeFrame: two weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Faculty of Medicine Ramathibodi Hospital
Study officials:
affiliation: Faculty of Medicine Ramathibodi Hospital
name: Sirimon Reutrakul, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Chirakalwasan N, Amnakkittikul S, Wanitcharoenkul E, Charoensri S, Saetung S, Chanprasertyothin S, Chailurkit LO, Panburana P, Bumrungphuet S, Thakkinstian A, Reutrakul S. Continuous Positive Airway Pressure Therapy in Gestational Diabetes With Obstructive Sleep Apnea: A Randomized Controlled Trial. J Clin Sleep Med. 2018 Mar 15;14(3):327-336. doi: 10.5664/jcsm.6972.
Clinical trial NCT04229797: Mandibular First Molar Distalization
Official title: The Efficacy of Mandibular First Molar Distalization Using Extra Radicular Miniscrews in Class III Patients: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Class III Malocclusion
Keywords: Class III malocclusion
Mandibular buccal shelf
Mini-screws
Extra-radicular mini-screws
Distalization
Temporary Anchorage device
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-01-18
Enrollment: 20
Sex: ALL
Minimum age (years): 16
Maximum age (years): 24
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A clinical study to test the capability of the mini-screws inserted in the Mandibular buccal shelf area as an anchorage unit to distalize mandibular first molar for correction of mild to moderate Class III cases. The second aim was to detect if there is a difference in the amount of distalization in the presence of unerupted mandibular third molars, using the same technique.

Detailed description: Class III malocclusion in adults is one of the most complex malocclusions in clinical orthodontics. For adults, the ideal treatment option for Class III malocclusion is accomplished either by camouflage treatment in mild to moderate cases or orthognathic surgery in severe cases. Camouflage treatment for Class III malocclusion comprises three main techniques; Class III elastics, mandibular first molar distalization, or extraction of mandibular first premolars. Mandibular first molar distalization via the use of skeletal anchorage has the problem of increased failure rate of the inter-radicular temporary anchorage devices (TADs). Accordingly, a randomized clinical trial using extra radicular TADs in the Mandibular buccal shelf area was designed in the current research aiming to test the efficacy of such a technique in inducing mandibular molar distalization with decreased failure rate, and whether the presence of unerupted mandibular third molars will affect the distalization movement or not.

Eligibility criteria: Inclusion Criteria:

* Class III dental incisal relation.
* Dental canine and molar relation not more than half unit Class III.
* Presence of unerupted mandibular third molars on both sides.
* Skeletal Class I or mild Class III.
* Full Permanent dentition.
* Medically free subjects.

Exclusion Criteria:

* Patients with systemic diseases or neuromuscular disorders.
* Retroclined lower incisors.
* Sever skeletal dysplasia.
* Patients with periodontal disease.

Primary outcomes:
measure: Dental effect
timeFrame: 6 months
Secondary outcomes:
measure: Skeletal and soft tissue effect
timeFrame: 6 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Dentistry, Cairo University
state: Giza
Study officials:
References:
Clinical trial NCT03599297: Bilateral Synchronous Simultaneous Stone Surgery
Official title: Evaluation of Efficacy and Safety Profile of Bilateral Synchronous Simultaneous Stone Surgery for Kidney Stones
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Kidney Calculi
Nephrolithotomy, Percutaneous
Ureteroscopy
Lead sponsor: Marmara University
Sponsor class: OTHER
First posted: 2018-07-26
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Advancements in technology and endourological armamentarium provides multiple surgical options for complicated stone patients. To avoid multiple operations and shorten the total operation durations, bilateral synchronous simultaneous stone surgery (BSSSS) has been popularized in recent years.

Our aim is to evaluate the preliminary outcomes of BSSSS in patients undergoing supine percutaneous nephrolithotomy (PCNL) and retrograde intrarenal surgery (RIRS).


Eligibility criteria: Inclusion Criteria:

* patients scheduled for kidney stone surgery according to European Association Urology, Urolithiasis guidelines
* patients with bilateral kidney stones

Exclusion Criteria:

* none

Primary outcomes:
measure: Stone free rate
timeFrame: at the 24th hour of the surgery
Secondary outcomes:
measure: Complications
timeFrame: at the 1st week of surgery
measure: Post operative urinary diversion
timeFrame: at the 24th hour of surgery
measure: Radiation exposure
timeFrame: At 1st hour of surgery
measure: Hemoglobin level change
timeFrame: from baseline to 24th hour of surgery
measure: Hospital stay
timeFrame: will be assessed through completion of study, an average of 1 year.
measure: Residual stone
timeFrame: at the 24th hour of surgery
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Marmara University Hospital
Study officials:
affiliation: Marmara University, School of Medicine, Department of Urology
name: Yiloren Tanidir, Ass. Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04314297: Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
Official title: Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Anlotinib
Durvalumab
Small Cell Lung Cancer
Lead sponsor: Wuhan Union Hospital, China
Sponsor class: OTHER
First posted: 2020-03-19
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study


Eligibility criteria: Inclusion Criteria:

- The subjects volunteered to join the study and signed the informed consent form. They had good compliance and cooperated with the follow-up; Patients between 18-75 years old; Extensive small cell lung cancer confirmed by histopathology (according to Veterans Administration lung study group, Valg stage) and did not progress after 4-6 cycles (21 days as a cycle) of first-line standard chemotherapy platinum combined with etoposide \[complete remission (CR), partial remission (PR) or stable (SD) according to recist1.1 standard\]; The time interval between the first TRT and the end of the last chemotherapy should be less than or equal to 6 weeks; The life expectancy shall be at least 3 months; ECoG score: 0-1

Exclusion Criteria:

- Small cell lung cancer patients with other pathological types of tumor species; Patients with pathological fracture in bone metastasis of small cell lung cancer; Patients with central nervous system metastasis; Patients who have received chest radiotherapy before; Patients who have used vasotargeted drugs (such as bevacizumab, sunitinib, etc.) including enrotinib and immunosuppressive agents before; Imaging (CT or MRI) showed that the distance between the tumor focus and the large blood vessel was less than or equal to 5 mm, or there was a central tumor invading the local large blood vessel, or there was an obvious cavitary or necrotic tumor in the lung;

Primary outcomes:
measure: progress free survival(PFS)
timeFrame: 1 year
Secondary outcomes:
measure: Overall survival(OS)
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02485197: Muscle Metabolic Function in Older Adults With Different Vitamin D Status Before and After Exercise
Official title: A Pilot Study Investigating Differences in Muscle Metabolic Function in Individuals Aged 65-75 Years With Different Vitamin D Status Before and After 7-days of Aerobic Training
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vitamin D Deficiency
Keywords: Muscle Metabolic Function
Vitamin D Status
25(OH)D
Older Adults
Lead sponsor: University of Kentucky
Sponsor class: OTHER
First posted: 2015-06-30
Enrollment: 7
Sex: ALL
Minimum age (years): 65
Maximum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: This is a small pilot aerobic training trial designed to examine differences between normal-high and low vitamin D levels and 7-days of aerobic training on local VO2 measured by non-invasive Hybrid Diffuse Optical Spectroscopy.


Eligibility criteria: Inclusion Criteria:

* 65-75 years of age

Exclusion Criteria:

* Currently have or have a history of cardiovascular or pulmonary disease that would preclude the involvement in the performance of exercise.
* Uncontrolled diabetes or hypertension.
* History of neurological conditions related to spinal derangement, disk disease, peripheral neuropathies, tremor and rigidity
* History of leg/hip trauma, inflammation, infection rhabdomyolysis, or leg surgery in the past 3 months
* Have a diagnosis of osteoporosis (as determined by DXA)
* Participated in a resistance or aerobic training program in the last 3 months
* Engage in more than 1 hr/week of vigorous activity
* Body mass index \>29
* On hormone replacement therapy

Primary outcomes:
measure: Muscle VO2 consumption
timeFrame: Up to 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lexington
country: United States
facility: University of Kentucky
state: Kentucky
Study officials:
affiliation: University of Kentucky
name: David T Thomas, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Kentucky
name: Maja Redzic, MS
role: STUDY_DIRECTOR
References: